Florida-based microsurgical robotics company, Medical Microinstruments, Inc. (MMI) has received approval from the US Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the first-ever clinical study using robotic microsurgery in patients with Alzheimer’s disease.
The feasibility study (NCT07178210), named REMIND (Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease), will collect safety and effectiveness data of the Symani Surgical System and microsurgical techniques to reestablish lymphatic drainage pathways in the deep cervical lymph nodes (dCLNs) of patients with Alzheimer’s and confirmed lymphatic obstruction.
A New Frontier in Alzheimer’s Treatment
The IDE approval signals regulatory recognition of a potential surgical pathway for addressing Alzheimer’s disease — an area historically dominated by drug-based therapies. The REMIND study will assess the safety and effectiveness of MMI’s Symani Surgical System, a robotic platform designed to perform delicate microsurgical procedures with submillimeter precision.
The surgery aims to restore blocked lymphatic drainage pathways from the brain by reconnecting deep cervical lymph nodes (dCLNs) to nearby veins. This could enable the clearance of neurotoxic proteins, such as amyloid beta and tau, which accumulate in Alzheimer’s patients and contribute to disease progression.
“This FDA approval is more than a milestone for our company—it’s a signal of what’s possible in science when we bring together the right experts, technology, and research,” said Mark Toland, CEO of MMI. “We’re at the threshold of a new era in microsurgery, where robotic precision could unlock novel treatment pathways for devastating diseases like Alzheimer’s.”
The REMIND feasibility study will evaluate device-related safety and patient outcomes over six months. The primary endpoint focuses on device-related serious adverse events within 30 days post-surgery, while secondary endpoints include biomarker analysis, imaging results, and cognitive assessments.
Patient enrollment will begin soon at leading research institutions across the US and Europe. MMI expects the study to lay the foundation for future robotic applications in neurology, expanding the possibilities for microsurgery beyond traditional soft-tissue repair.
Precision at the Limits of Human Capability
Operating on dCLNs requires extreme accuracy — the lymphatic vessels involved can be as small as 0.2 millimeters, thinner than two sheets of paper. Such procedures are nearly impossible for the human hand to perform consistently without robotic assistance.
MMI’s Symani System enables surgeons to perform these micro-scale interventions using tremor-reducing and motion-scaling technologies. The system’s miniature wristed instruments make it possible to connect tiny lymphatic and venous structures, potentially improving the brain’s ability to drain harmful waste and reduce inflammation.
“The REMIND study opens an entirely new chapter in the treatment of neurodegenerative disease,” said Kate Rumrill, MMI’s Chief Scientific Officer. “Bringing robotic precision to more surgeons could transform patient outcomes and pave the way for future treatments that directly target the biological mechanisms of Alzheimer’s.”
Although most Alzheimer’s research has centered on drug therapies, there is growing interest in surgical and interventional approaches that target the disease’s underlying biology. Recent studies have explored methods like lymphatic microsurgery, deep brain stimulation, and focused ultrasound to improve clearance of amyloid plaques or enhance neuronal function.
Robotic-assisted techniques, such as those pioneered by MMI, could make these intricate interventions safer and more reproducible. Early evidence suggests that improving lymphatic drainage from the brain may help clear neurotoxins and slow cognitive decline. While such surgical strategies remain experimental, the FDA’s IDE approval represents a major step toward establishing their clinical potential.
The REMIND study is the latest milestone in MMI’s expansion into neurological applications, coming just months after the company performed the first-ever robotic intracranial brain surgery.
